Semaglutide Shows Surprising Mental Health Benefits in Massive 100,000-Person Study

Registry-based study using Swedish national registers followed nearly 100,000 people from 2009 to 2022.

The cohort included more than 20,000 people who used GLP-1 medications.

Periods of semaglutide use were associated with a 42% lower risk of psychiatric-related hospitalizations and sick leave.

Semaglutide use periods tied to a 44% lower depression risk and 38% lower anxiety risk; GLP-1 treatment periods saw 47% lower hospital care and sick leave for substance use.

GLP-1 receptor agonists were linked to reduced suicidal behavior risk; the study was conducted by researchers from University of Eastern Finland, Karolinska Institutet, and Griffith University.